Takeda

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Takeda CEO succession confirmed as Weber plans retirement

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

News

INTERCEPT trial team at a meeting in Vienna

Takeda backs biomarker trial for Crohn's prevention

The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

Sales & Marketing

Go slow to go fast: Setting a content transformation journey...

Pharma marketing is evolving and it’s evolving quickly. How can organisations successfully ride the wave of this transformation?

News

NICE turns down Takeda colorectal cancer drug

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Shifting the paradigm in pharma marketing with content trans...

Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.

Takeda scores with polycythemia vera drug in phase 3 trial

Takeda CEO succession confirmed as Weber plans retirement

Takeda backs biomarker trial for Crohn's prevention

Go slow to go fast: Setting a content transformation journey...

NICE turns down Takeda colorectal cancer drug

Shifting the paradigm in pharma marketing with content trans...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Takeda

Editor's Picks